Features
The pace of change in the life sciences industry is startling and is putting traditional IP management strategies under extreme pressure. It may be time for IP leaders to start looking to the tech industry experience for lessons in how to respond.
Insurance products relating to patents and other rights are not new, but they have never really taken off. Now, though, the industry's heavy hitters are moving in and things could be about to change.
“The patent market has fully stabilised and prices are rational,” said no one ever. During 2018 total dollars transacted in brokered deals increased while prices of single-asset deals have dropped significantly.
Boards and directors typically prioritise non-IP issues on the corporate agenda; however, legal requirements and market activities suggest that this might be a serious misstep.
Interconnectivity is the key to maximising IoT's potential - and that means finding effective ways to ensure access to the IP required to make it happen.
The heads of intellectual property at Swedish automaker Volvo Car Corporation and Swiss wireless communications supplier u-blox AG believe that the EPO must play a central role in deciding on mobile technology SEPs.
Life sciences companies in the United States are under increasing pressure. Campaigners for changes to the patent system are working to prevent what they see as abusive practices – and it looks as if they are winning the argument.
Just months after a private equity takeover, RPX has appointed an industry veteran as its new CEO. But with a declining financial performance and questions remaining over the future of its discovery business, Dan McCurdy (left) will need all of his experience to turn around one of the patent market’s most iconic businesses.
How to ensure that the use of open source packages does not run contrary to corporate IP policies.
Columns
Negative know-how, an often-overlooked trade secret, can generate surprising value, especially where competition is most heated.
The scale and size of the risks associated with IP-facing companies is significant and rising. The ISO standard for risk management helps to re-conceptualises it.
A pair of recent decisions from the Federal Court of Australia suggest that it may be about to become more difficult for drug patent owners to prevail in requests for interlocutory injunctions.
Insights
The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative.
Some of the major stories carried on the IAM platform in October and November.
Data centre
A selection of key IP facts and figures, as reported by IAM and other sources.
